296 related articles for article (PubMed ID: 24122977)
1. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
2. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
3. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
4. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
5. Investigational therapies targeting the ErbB family in oesophagogastric cancer.
Moorcraft SY; Chau I
Expert Opin Investig Drugs; 2014 Oct; 23(10):1349-63. PubMed ID: 24949530
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor: an important target in esophageal cancer.
Hong L; Han Y; Brain L
Expert Opin Ther Targets; 2013 Oct; 17(10):1179-85. PubMed ID: 23855932
[TBL] [Abstract][Full Text] [Related]
8. Novel targets in gastric and esophageal cancer.
Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
[TBL] [Abstract][Full Text] [Related]
9. Targetting esophageal and gastric cancers with monoclonal antibodies.
Norguet E; Dahan L; Seitz JF
Curr Top Med Chem; 2012; 12(15):1678-82. PubMed ID: 22978338
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
12. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
Moon C; Chae YK; Lee J
Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
[TBL] [Abstract][Full Text] [Related]
13. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for esophageal cancer.
Homs MY; Voest EE; Siersema PD
Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in gastroesophageal cancer.
Kasper S; Schuler M
Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
[TBL] [Abstract][Full Text] [Related]
16. Emerging tyrosine kinase inhibitors for esophageal cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2013 Jun; 18(2):219-30. PubMed ID: 23725567
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Hong TS; Wo JY; Kwak EL
Semin Radiat Oncol; 2013 Jan; 23(1):31-7. PubMed ID: 23207045
[TBL] [Abstract][Full Text] [Related]
18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
20. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
